Private Equity Firm Offers Unusually High Amount For Singapore’s AsiaPharm
This article was originally published in PharmAsia News
Executive Summary
A private equity firm has offered to acquire Singapore's AsiaPharm for U.S. $252 million and take the company private. The move is seen as a way to allow the injectables maker to acquire companies in mainland China where authorities are overhauling the drug regulation system. AsiaPharm executives, who own more than 44 percent of their firm's stock, have agreed to the deal. Such private equity deals in Asia generally are valued at much less than the offer by MBK Partners for AsiaPharm, keeping mergers and acquisition attractive propositions. (Click here for more - a subscription may be required